Clinical trials: Overweight, Obesity
Overweight/Obesity
STELLA® Endogastric Balloon System. Evaluation of Safety and Introduction System at 7 Months.
The main objective of the study was to evaluate the safety of the introduction of STELLA® endogastric balloon and the endogastric balloon itself at 7 months.
- Trial name
- NCT06744829
- Testing
- Balloon placement and inflation and removal of the Balloon
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Mikromic Medical, S. L
Obesity, Nutritional and Metabolic Diseases
A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients
This study investigates the effectiveness and safety of 12 weeks of treatment with JNJ-16269110 (R256918), in overweight and obese patients.
- Conditions
- Obesity, Nutritional and Metabolic Diseases, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT00622765
- Testing
- R256918
- Where
- 18 sites in Belgium, Denmark and 5 more
- Volunteers
- 321 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight, Obesity
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine.
- Trial name
- NCT03842202
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight.
- Trial name
- NCT07662122
- Testing
- BI 3034701
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 344 people
- Sponsor
- Boehringer Ingelheim
Hypertension
International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan
The purpose of this study is to estimate antihypertensive effect of azilsartan medoxomil (Edarbi®) therapy on blood pressure in participants with overweight or obesity in routine clinical practice of hypertension (HTN) treatment…
- Trial name
- NCT02756819
- Testing
- Azilsartan Medoxomil
- Where
- 66 sites in Kazakhstan, Russia
- Volunteers
- 1,945 people
- Sponsor
- Takeda
Obesity & Overweight
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general.
- Trial name
- NCT07728383
- Testing
- Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Gila Therapeutics, Inc.
Hypertension
A Study of VCT220 in Participants With Hypertension and Obesity or Overweight
The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.
- Trial name
- VICTOR-HTN (NCT07360275)
- Testing
- VCT220 Tablet
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Vincentage Pharma Co., Ltd
Obesity
PINS Stimulator System for Deep Brain Stimulation to Treat Obesity
The purpose of this clinical study is to verify the long term effecacy and safety of a bilateral deep brain stimulation (DBS) produced by Beijing PINS Medical Co., Ltd. as a treatment option for patients with obesity.
- Trial name
- NCT02254395
- Testing
- Deep Brain Stimulation
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Beijing Pins Medical Co., Ltd
Obesity
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06568731
- Testing
- Danuglipron
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Effects of the GOLO for Life System Diet With and Without GOLO Release Supplement on Glycemic Control and Insulin Resistance
This randomized, double-blind placebo-controlled study is intended to observe the short-term effects of the GFL System Diet with Release supplement versus GFL System Diet with placebo on glycemic metabolism and insulin resistance…
- Trial name
- NCT04082390
- Testing
- RELEASE
- Volunteers
- 36 people
- Sponsor
- Golo
Obesity
Safety and Tolerance of a Nutritional Intervention Program- In.Form 1.2
The study evaluated and the safety, tolerance and acceptability of a lifestyle modification program with nutritional supplementation in generally healthy overweight subjects with cardiometabolic risk factors.
- Trial name
- NCT03098056
- Testing
- PROG2
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nature's Sunshine Products, Inc.
Cardiovascular Risk Factor
A Pilot Study to Investigate the Effect of Water-soluble Tomato Extract on TMAO
To determine the effect of 4 weeks daily consumption of Fruitflow on changes in plasma levels of fasting Trimethylamine N-oxide concentrations (TMAO)
- Trial name
- NCT04160481
- Testing
- FruitFlow
- Where
- Ireland
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Overweight
Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to a Calorie-Restricted Diet in Women
The purpose of this study is to examine the effectiveness of the South Beach Diet™ and South Beach Diet™ products compared to a traditional calorie restricted diet.
- Trial name
- NCT00932516
- Testing
- South Beach Diet™ with South Beach Diet™ Products, South Beach Diet™, Calorie restricted diet with South Beach Diet™ Products
- Where
- 4 sites in United States
- Volunteers
- 248 people
- Sponsor
- Mondelēz International, Inc.
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes
GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the treatment of T2DM.
- Trial name
- NCT00376038
- Testing
- GSK189075 oral tablets, metformin tablets
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- GlaxoSmithKline
Metabolism and Nutrition Disorder, Obesity
Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics of single doses of NNC0174-0833 in normal weight, overweight to obese but…
- Trial name
- NCT02300844
- Testing
- NNC0174-0833
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Prader-Willi Syndrome
A Study of Pitolisant in Patients With Prader-Willi Syndrome
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome.
- Trial name
- NCT06366464
- Testing
- Pitolisant tablet
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 134 people
- Sponsor
- Harmony Biosciences Management, Inc.
Obesity
Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug
Experiment in the test tube indicated that CP-945,598 becomes less soluble with increase of pH (less acidity). Changes in stomach acid levels may affect the solubility of CP-945,598, therefore, alters its availability in the…
- Trial name
- NCT00644839
- Testing
- CP-945,598
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity
This randomized, double-blind placebo-controlled study was intended to measure the effects of the GWMP with Release supplement versus GWMP with placebo supplement in a representative group of obese subjects with or without…
- Trial name
- NCT03842501
- Testing
- Release Supplement
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Golo
Insulin Resistance, Obesity
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes
The purpose of this study is to determine whether the investigational drug INCB013739 has an effect on systemic and adipose tissue 11-HSD1 activity in obese, insulin resistant subjects.
- Trial name
- NCT00398619
- Testing
- INCB13739
- Where
- 2 sites in United States
- Sponsor
- Incyte Corporation
Obesity and Overweight
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea
This study is conducted to investigate the safety and effectiveness of semaglutide in participants with obesity and overweight in routine clinical practice. Participants will get semaglutide as prescribed by a doctor.
- Trial name
- NCT07018544
- Testing
- semaglutide
- Where
- 8 sites in South Korea
- Volunteers
- 840 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.